- Home
- ALMU vs DSGN Comparison
ALMU vs DSGN Comparison
Compare ALMU & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALMU
- DSGN
- Stock Information
- Founded
- ALMU 2019
- DSGN 2017
- Country
- ALMU United States
- DSGN United States
- Employees
- ALMU N/A
- DSGN N/A
- Industry
- ALMU Semiconductors
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- ALMU Technology
- DSGN Health Care
- Exchange
- ALMU Nasdaq
- DSGN Nasdaq
- Market Cap
- ALMU 206.9M
- DSGN 224.8M
- IPO Year
- ALMU N/A
- DSGN 2021
- Fundamental
- Price
- ALMU $14.26
- DSGN $3.73
- Analyst Decision
- ALMU
- DSGN Hold
- Analyst Count
- ALMU 0
- DSGN 1
- Target Price
- ALMU N/A
- DSGN $4.00
- AVG Volume (30 Days)
- ALMU 194.7K
- DSGN 91.9K
- Earning Date
- ALMU 05-07-2025
- DSGN 05-07-2025
- Dividend Yield
- ALMU N/A
- DSGN N/A
- EPS Growth
- ALMU N/A
- DSGN N/A
- EPS
- ALMU N/A
- DSGN N/A
- Revenue
- ALMU $3,627,488.00
- DSGN N/A
- Revenue This Year
- ALMU N/A
- DSGN N/A
- Revenue Next Year
- ALMU N/A
- DSGN N/A
- P/E Ratio
- ALMU N/A
- DSGN N/A
- Revenue Growth
- ALMU 335.67
- DSGN N/A
- 52 Week Low
- ALMU $2.50
- DSGN $2.60
- 52 Week High
- ALMU $18.00
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- ALMU N/A
- DSGN 48.52
- Support Level
- ALMU N/A
- DSGN $3.31
- Resistance Level
- ALMU N/A
- DSGN $4.13
- Average True Range (ATR)
- ALMU 0.00
- DSGN 0.31
- MACD
- ALMU 0.00
- DSGN 0.04
- Stochastic Oscillator
- ALMU 0.00
- DSGN 61.27
About ALMU Aeluma Inc. Common Stock
Aeluma Inc is a semiconductor company specializing in sensors and communications. It is developing sensor technology for mobile devices and vehicles. The company develops novel optoelectronic devices for sensing and communications applications. The company manufactures devices using high-performance compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass-market microelectronics. The applications include mobile, automotive, AI, defense & aerospace, communication, AR/VR and quantum computing.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.